Table 1.
The formulation, particle size, and specific surface area of the megestrol acetate solid dispersion nanoparticles prepared using the SAS process
| Formulation | Drug content (%) | Mean particle size (nm) | Specific surface area (m2/g) |
|---|---|---|---|
| Megestrol acetate:HPMC =1:2 | 95.1±2.6 | 135.8±18.2 | 96.16±1.69 |
| Megestrol acetate:PVP K30 =1:2 | 95.9±3.7 | 310.9±30.3 | 40.21±1.33 |
| Megestrol acetate:HPMC:Gelucire 44/14 =1:2:0.5 | 96.1±2.1 | 245.9±35.9 | 49.22±1.09 |
| Megestrol acetate:HPMC:poloxamer 407 =1:2:0.5 | 95.8±2.3 | 229.7±21.6 | 51.13±1.03 |
| Megestrol acetate:HPMC:Ryoto sugar ester L1695 =1:2:0.5 | 97.1±2.0 | 155.3±20.1 | 69.31±1.25 |
| Megestrol acetate:HPMC:TPGS =1:2:0.5 | 97.7±1.9 | 495.2±65.3 | 33.11±1.19 |
| Megestrol acetate:HPMC:Ryoto sugar ester L1695 =1:2:1 | 98.9±1.8 | 180.3±29.1 | 57.22±1.35 |
Notes:
The drug content (%) = weight of the loaded drug/weight of the feeding drug ×100. Data are expressed as mean ± standard deviation (n=3).
Abbreviations: SAS, supercritical antisolvent; HPMC, hydroxypropylmethyl cellulose; PVP, polyvinylpyrrolidone; TPGS, D-α-tocopheryl polyethylene glycol 1000 succinate.